{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:16:31Z","timestamp":1774926991679,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","award":["00-000-000"],"award-info":[{"award-number":["00-000-000"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","award":["M-CRADA EBI"],"award-info":[{"award-number":["M-CRADA EBI"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10875-020-00905-4","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T08:02:42Z","timestamp":1606464162000},"page":"335-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects"],"prefix":"10.1007","volume":"41","author":[{"given":"Cristiane J.","family":"Nunes-Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Sun","family":"Kuehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5550-9678","authenticated-orcid":false,"given":"Sergio D.","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"905_CR1","doi-asserted-by":"crossref","unstructured":"Sadat MA, Moir S, Chun TW, Lusso P, Kaplan G, Wolfe L, et al. Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N Engl J Med. 2014;370(17):1615\u201325.","DOI":"10.1056\/NEJMoa1302846"},{"issue":"2","key":"905_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1042\/BST20160182","volume":"45","author":"DS Alonzi","year":"2017","unstructured":"Alonzi DS, Scott KA, Dwek RA, Zitzmann N. Iminosugar antivirals: the therapeutic sweet spot. Biochem Soc Trans. 2017;45(2):571\u201382.","journal-title":"Biochem Soc Trans"},{"key":"905_CR3","volume-title":"Essentials of glycobiology [Internet]","author":"P Stanley","year":"2017","unstructured":"Stanley P, Taniguchi N, Aebi M. N-glycans. In: Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M, et al., editors. Essentials of glycobiology [Internet]. 3rd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2017.","edition":"3"},{"issue":"10","key":"905_CR4","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1128\/JVI.70.10.7153-7160.1996","volume":"70","author":"PB Fischer","year":"1996","unstructured":"Fischer PB, Karlsson GB, Dwek RA, Platt FM. N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure. J Virol. 1996;70(10):7153\u201360.","journal-title":"J Virol"},{"key":"905_CR5","doi-asserted-by":"crossref","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270\u20133.","DOI":"10.1038\/s41586-020-2012-7"},{"key":"905_CR6","unstructured":"World Health Organization. Virtual press conference on COVID-19 \u2013 11 March 2020 https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/transcripts\/who-audio-emergencies-coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb432bb3_22020"},{"key":"905_CR7","doi-asserted-by":"crossref","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"905_CR8","doi-asserted-by":"crossref","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected\u00a0pneumonia in Wuhan, China. JAMA. 2020;323(11):1061\u20139.","DOI":"10.1001\/jama.2020.1585"},{"key":"905_CR9","doi-asserted-by":"crossref","unstructured":"Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Sch\u00fcnemann HJ, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973\u201387.","DOI":"10.1016\/S0140-6736(20)31142-9"},{"key":"905_CR10","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamainternmed.2020.1562","volume":"180","author":"S Galea","year":"2020","unstructured":"Galea S, Merchant RM, Lurie N. The mental health consequences of COVID-19 and physical distancing: the need for prevention and early intervention. JAMA Intern Med. 2020;180:817\u20138.","journal-title":"JAMA Intern Med"},{"key":"905_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","volume":"78","author":"M Nicola","year":"2020","unstructured":"Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg. 2020;78:185\u201393.","journal-title":"Int J Surg"},{"issue":"34","key":"905_CR12","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1016\/j.vaccine.2020.06.056","volume":"38","author":"UH Kartoglu","year":"2020","unstructured":"Kartoglu UH, Moore KL, Lloyd JS. Logistical challenges for potential SARS-CoV-2 vaccine and a call to research institutions, developers and manufacturers. Vaccine. 2020;38(34):5393\u20135.","journal-title":"Vaccine."},{"issue":"2","key":"905_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 Spike glycoprotein. Cell. 2020;181(2):281\u201392.e6.","journal-title":"Cell"},{"issue":"6501","key":"905_CR14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","volume":"369","author":"Y Watanabe","year":"2020","unstructured":"Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369(6501):330\u20133.","journal-title":"Science."},{"key":"905_CR15","doi-asserted-by":"publisher","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","volume":"176","author":"B Coutard","year":"2020","unstructured":"Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir Res. 2020;176:104742.","journal-title":"Antivir Res"},{"key":"905_CR16","doi-asserted-by":"crossref","unstructured":"Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.","DOI":"10.1038\/s41467-020-15562-9"},{"issue":"11","key":"905_CR17","first-page":"e77","volume":"2","author":"J Chang","year":"2013","unstructured":"Chang J, Guo JT, Du Y, Block T. Iminosugar glucosidase inhibitors as broadly active anti-filovirus agents. Emerg Microbes Infect. 2013;2(11):e77.","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"905_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1042\/BST20200505","volume":"48","author":"SJ Williams","year":"2020","unstructured":"Williams SJ, Goddard-Borger ED. \u03b1-Glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19. Biochem Soc Trans. 2020;48(3):1287\u201395.","journal-title":"Biochem Soc Trans"},{"issue":"6485","key":"905_CR19","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444\u20138.","journal-title":"Science."},{"issue":"2","key":"905_CR20","first-page":"139","volume":"7","author":"MA Fischl","year":"1994","unstructured":"Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC, Fass RJ, et al. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200\u2013500 CD4 cells\/mm3. J Acquir Immune Defic Syndr (1988). 1994;7(2):139\u201347.","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"issue":"9","key":"905_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","volume":"6","author":"MC Patterson","year":"2007","unstructured":"Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6(9):765\u201372.","journal-title":"Lancet Neurol"},{"key":"905_CR22","doi-asserted-by":"crossref","unstructured":"Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003;26(6):513\u201326.","DOI":"10.1023\/A:1025902113005"},{"key":"905_CR23","doi-asserted-by":"crossref","unstructured":"Zhao P, Praissman JL, Grant OC, Cai Y, Xiao T, Rosenbalm KE, et al. Virus-receptor interactions of glycosylated SARS-CoV-2 Spike and human ACE2 receptor. bioRxiv. 2020.","DOI":"10.2139\/ssrn.3641894"},{"key":"905_CR24","doi-asserted-by":"publisher","unstructured":"Shajahan A, Archer-Hartmann S, Supekar NT, Gleinich AS, Heiss C, Azadi P. Comprehensive characterization of N- and O-glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.05.01.071688.","DOI":"10.1101\/2020.05.01.071688"},{"issue":"3","key":"905_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/pds.3760","volume":"24","author":"M Brand","year":"2015","unstructured":"Brand M, Muller A, Alsop J, van Schaik IN, Bembi B, Hughes D. Results from a 9-year intensive safety surveillance scheme (IS(3) ) in miglustat (Zavesca(\u00ae) )-treated patients. Pharmacoepidemiol Drug Saf. 2015;24(3):329\u201333.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"905_CR26","doi-asserted-by":"crossref","unstructured":"Fukushi M, Yoshinaka Y, Matsuoka Y, Hatakeyama S, Ishizaka Y, Kirikae T, et al. Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus. J Virol. 2012;86(21):11745\u201353.","DOI":"10.1128\/JVI.01250-12"},{"key":"905_CR27","doi-asserted-by":"crossref","unstructured":"Zhao X, Guo F, Comunale MA, Mehta A, Sehgal M, Jain P, et al. Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. Antimicrob Agents Chemother. 2015;59(1):206\u201316.","DOI":"10.1128\/AAC.03999-14"},{"issue":"7","key":"905_CR28","doi-asserted-by":"publisher","first-page":"e00127","DOI":"10.1128\/JVI.00127-20","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-20.","journal-title":"J Virol."},{"issue":"4","key":"905_CR29","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894\u2013904.e9.","journal-title":"Cell"},{"key":"905_CR30","doi-asserted-by":"crossref","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260\u20133.","DOI":"10.1126\/science.abb2507"},{"key":"905_CR31","doi-asserted-by":"crossref","unstructured":"Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215\u201320.","DOI":"10.1038\/s41586-020-2180-5"},{"issue":"5","key":"905_CR32","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284\u201394.e9.","journal-title":"Cell."},{"key":"905_CR33","doi-asserted-by":"publisher","unstructured":"Mehdipour AR, Hummer G. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.09.193680.","DOI":"10.1101\/2020.07.09.193680"},{"key":"905_CR34","doi-asserted-by":"crossref","unstructured":"Procko E. The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2. bioRxiv. 2020.","DOI":"10.1101\/2020.03.16.994236"},{"key":"905_CR35","doi-asserted-by":"crossref","unstructured":"Walls AC, Tortorici MA, Snijder J, Xiong X, Bosch BJ, Rey FA, et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci U S A. 2017;114(42):11157\u201362.","DOI":"10.1073\/pnas.1708727114"},{"issue":"14","key":"905_CR36","doi-asserted-by":"publisher","first-page":"e00635","DOI":"10.1128\/JVI.00635-20","volume":"94","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Yu D, Yan H, Chong H, He Y. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J Virol. 2020;94(14):e00635-20.","journal-title":"J Virol."},{"key":"905_CR37","doi-asserted-by":"crossref","unstructured":"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30(4):343\u201355.","DOI":"10.1038\/s41422-020-0305-x"},{"issue":"5","key":"905_CR38","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1172\/JCI137647","volume":"130","author":"SF Pedersen","year":"2020","unstructured":"Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202\u20135.","journal-title":"J Clin Invest"},{"key":"905_CR39","doi-asserted-by":"crossref","unstructured":"Warfield KL, Plummer E, Alonzi DS, Wolfe GW, Sampath A, Nguyen T, et al. A novel iminosugar UV-12 with activity against the diverse viruses influenza and dengue (novel iminosugar antiviral for influenza and dengue). Viruses. 2015;7(5):2404\u201327.","DOI":"10.3390\/v7052404"},{"key":"905_CR40","doi-asserted-by":"crossref","unstructured":"Riethmueller S, Somasundaram P, Ehlers JC, Hung CW, Flynn CM, Lokau J, et al. Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation. PLoS Biol. 2017;15(1):e2000080.","DOI":"10.1371\/journal.pbio.2000080"},{"issue":"8","key":"905_CR41","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.4049\/jimmunol.160.8.4034","volume":"160","author":"P Proost","year":"1998","unstructured":"Proost P, Struyf S, Couvreur M, Lenaerts JP, Conings R, Menten P, et al. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J Immunol. 1998;160(8):4034\u201341.","journal-title":"J Immunol"},{"issue":"21","key":"905_CR42","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","volume":"383","author":"AB Cavalcanti","year":"2020","unstructured":"Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020;383(21):2041\u201352.","journal-title":"N Engl J Med."},{"issue":"26","key":"905_CR43","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMc2021225","volume":"382","author":"MR Mehra","year":"2020","unstructured":"Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. DOI: 10.1056\/NEJMoa2007621. N Engl J Med. 2020;382(26):2582.","journal-title":"N Engl J Med"},{"issue":"10240","key":"905_CR44","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/S0140-6736(20)31324-6","volume":"395","author":"MR Mehra","year":"2020","unstructured":"Mehra MR, Ruschitzka F, Patel AN. Retraction-hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820.","journal-title":"Lancet."},{"key":"905_CR45","doi-asserted-by":"publisher","unstructured":"Rajasekharan S, Bonotto RM, Kazungu Y, Alves LN, Poggianella M, Orellana PM, et al. Repurposing of miglustat to inhibit the coronavirus severe acquired respiratory syndrome SARS-CoV-2. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.05.18.101691.","DOI":"10.1101\/2020.05.18.101691"},{"issue":"1","key":"905_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coviro.2012.11.004","volume":"3","author":"P Zhong","year":"2013","unstructured":"Zhong P, Agosto LM, Munro JB, Mothes W. Cell-to-cell transmission of viruses. Curr Opin Virol. 2013;3(1):44\u201350.","journal-title":"Curr Opin Virol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00905-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-020-00905-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00905-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T03:01:42Z","timestamp":1697252502000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-020-00905-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s10875-020-00905-4","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"CJNS, HSK, and SDR declare that they have no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}